[Type 2 diabetes mellitus: new treatments]

Area of Science:

• Endocrinology
• Pharmacology
• Metabolic Diseases

Background:

• Traditional hypoglycemic drugs present challenges like beta-cell failure, hypoglycemia, and weight gain, potentially worsening diabetes.
• Current therapeutic options aim to improve diabetes management and patient outcomes.

Purpose of the Study:

• To review the benefits and drawbacks of traditional hypoglycemic agents.
• To discuss newer classes of hypoglycemic drugs, including their mechanisms and efficacy.
• To emphasize the need for personalized treatment strategies in diabetes management.

Main Methods:

• Literature review of traditional and novel hypoglycemic drugs.
• Analysis of drug mechanisms, including incretin effects and renal glucose reabsorption inhibition.
• Discussion of clinical outcomes such as glycosylated hemoglobin reduction, hypoglycemia, and weight changes.

Main Results:

• Incretin-based therapies (GLP-1 agonists, DPP-4 inhibitors) reduce HbA1c without hypoglycemia or weight gain.
• Sodium-glucose cotransporter type 2 inhibitors show efficacy by inhibiting renal glucose reabsorption.
• Long-term effects and cardiovascular benefits of SGLT2 inhibitors require further investigation.

Conclusions:

• Modern pharmacotherapy offers better diabetes control, but an ideal hypoglycemic drug remains elusive.
• Personalized treatment, considering individual factors like HbA1c, risks, and cardiovascular health, is crucial.
• Combination therapy is often necessary for optimal glycemic control in most patients.